Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Pharmacokinetic Trial of RGB-03 vs MabThera in Rheumatoid Arthritis
NCT02371096Phase 1Unknown
- Sponsor
- Gedeon Richter Plc
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of rituximab biosimilar RGB-03 in rheumatoid arthritis (RA) (2 arms), sponsored by Gedeon Richter Plc. Primary endpoint: Area under the serum concentration versus time curve. Status: unknown.
02
Drugs
rituximab biosimilar RGB-03
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02371096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371096.